TriSalus Life Sciences (TLSI) Shares Outstanding (Weighted Average) (2020 - 2026)

TriSalus Life Sciences has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $51.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 80.67% year-over-year to $51.5 million; the trailing twelve-month figure through Mar 2026 stood at $51.5 million (up 80.67% YoY), and the FY2025 full-year result was $7.4 million, up 1.25% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $51.5 million, up from $7.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $51.5 million in Q1 2026, with the low at $299936.0 in Q3 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $18.6 million across 5 years, with a median of $16.2 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) tumbled 98.8% — and 2023, when it jumped 4656.55%.
• TriSalus Life Sciences' Shares Outstanding (Weighted Average) stood at $15.8 million in 2022, then plunged by 47.65% to $8.3 million in 2023, then decreased by 11.72% to $7.3 million in 2024, then grew by 1.25% to $7.4 million in 2025, then surged by 596.24% to $51.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $51.5 million (Q1 2026), $7.4 million (Q4 2025), and $34.9 million (Q3 2025), per Business Quant data.